{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-059044","form_type":"8-K","ticker":"ABVC","cik":"0001173313","company_name":"ABVC BIOPHARMA, INC.","filed_at":"2023-07-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.300002+00:00","generated_at":"2026-06-13T04:02:46.420811+00:00","sec_items":["2.02","3.03","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ABVC BioPharma executes 1-for-10 reverse stock split effective July 25, 2023 to regain Nasdaq compliance","bullets":["1-for-10 reverse stock split effective 12:01 a.m. EST July 25, 2023; new CUSIP 00091F 304.","Pre-split outstanding shares 33,080,740; post-split approx 3,308,074 (no fractional shares, rounded up).","Shareholder approval obtained at special meeting on July 7, 2023.","Ticker symbol remains ABVC; split aims to increase per-share price to meet Nasdaq continued listing standards.","Board expects reverse split to help exit penny-stock status and attract broader investor base."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-059044","json":"https://secwatch.observer/filing/0001213900-23-059044.json","markdown":"https://secwatch.observer/filing/0001213900-23-059044.md","text":"https://secwatch.observer/filing/0001213900-23-059044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023059044/0001213900-23-059044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023059044/ea182176-8k_abvcbio.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T04:02:46.420811+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cfcfa36215be8944aef272bc4841d34f04d963db","claim":"ABVC BIOPHARMA, INC.: Filed a Certificate of Amendment to Articles of Incorporation to effect a 1-for-10 reverse stock split (effective 2023-07-25).","evidence_excerpt":"ABVC BioPharma, Inc. (the “Company”) filed a Certificate of Amendment to its Articles of Incorporation (the “Certificate”) to be effective as of 12:01 a.m. EST on July 25, 2023 authorizing a 1-for-10 reverse stock split of the issued and outstanding shares of its common stock","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023059044/0001213900-23-059044-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-07-25"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}